{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-012870","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2023-04-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.407093+00:00","generated_at":"2026-06-17T01:55:05.062719+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Trevi Therapeutics amends bylaws to update proxy rules and meeting procedures","bullets":["Eliminated requirement for stockholder list to be available at meeting.","Added provisions for adjourning meetings due to technical failure in remote communication.","Enhanced disclosure requirements for stockholder nominations under universal proxy rules (Rule 14a-19).","Company may disregard nominations if stockholders fail to comply with Rule 14a-19 solicitation requirements."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-012870","json":"https://secwatch.observer/filing/0000950170-23-012870.json","markdown":"https://secwatch.observer/filing/0000950170-23-012870.md","text":"https://secwatch.observer/filing/0000950170-23-012870.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000095017023012870/0000950170-23-012870-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000095017023012870/trvi-20230413.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T01:55:05.062719+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7866dad4bcc75f9af29acf8555ad6bf0a5712277","claim":"Trevi Therapeutics, Inc.: On April 13, 2023, the Board approved an amendment and restatement of the bylaws to eliminate the requirement to make the stockholder list available during meetings, address adjournment due to technical failures in remote meetings, and revise procedural mechanics and disclosure requirements in light (effective 2023-04-13).","evidence_excerpt":"On April 13, 2023, the Board of Directors of Trevi Therapeutics, Inc. (the “Company”) approved an amendment and restatement of the Company’s amended and restated bylaws (as so amended and restated, the “Amended and Restated Bylaws”), effective immediately.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017023012870/0000950170-23-012870-index.htm","confidence":0.98,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-04-13"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}